RoosterBio and MBL Beijing Biotech Partner to Accelerate Manufacturing of Advanced Therapies in China


RoosterBio, Inc., has entered into an exclusive distribution partnership with MBL Beijing Biotech.

We are excited to partner with the team at MBL Beijing to accelerate the development of cell and exosome products and help bring these innovative therapies to patients in China.

— Tim Kelly, CEO of RoosterBio

FREDERICK, MARYLAND, USA, Aug. 30, 2022 / — RoosterBio, Inc., a leading provider of human mesenchymal stem/stromal cells (hMSCs), highly technical media, and biotechnology development services bioprocesses, announced today that it has entered into an exclusive distribution partnership with MBL Beijing Biotech (MBL Beijing), a JSR Life Sciences company providing cutting-edge products to support life sciences. Under the agreement, RoosterBio’s expansion media, exosome collection media, bioreactor media and genetic engineering media will be sold and distributed by MBL Beijing, making them readily available for the first time. both to MSC and exosome therapy developers in China.

“RoosterBio’s technical media products are creating transformative impact for cell and exosome therapy developers worldwide,” said Tim Kelly, CEO of RoosterBio. “One of our main goals in 2022 is to expand global access to our best products and services, particularly in Europe and Asia. Some of the most exciting R&D activities in the area of ​​MSCs and exosomes are conducted in China, which is why we sought to partner with an industry leader in that region. MBL Beijing quickly emerged as the obvious choice for this collaboration based on its outstanding track record of supporting to researchers across China to provide not only high-quality products, but also comprehensive solutions to drug development challenges.We are delighted to partner with the team at MBL Beijing to accelerate the development of cell and drug products. exosomes and help deliver these innovative therapies to patients in China.

In addition to product distribution, the agreement creates a pathway to RoosterBio’s process development and analytical services, which have helped advanced therapy developers around the world accelerate the clinical entry of leading candidates. These services combined with media solutions provide therapy developers with a comprehensive solution, addressing upstream expansion of hMSCs into 2D flasks or 3D bioreactors, optimized conditions for exosome collection, and downstream processes to achieve the purity, yield and potency of the final formulated drug product.

“China has a strong focus on MSC and exosome therapies and we have been impressed with RoosterBio’s products and services designed to support this market,” said Tamao Kaku, General Manager of MBL Beijing. “After evaluating the current solutions available, we have determined that drug developers in China will greatly benefit from RoosterBio’s technology platform and product portfolio. We are delighted to have the opportunity to support our cell and exosome therapy developers by offering this cutting-edge solution.

MBL Beijing will begin accepting and fulfilling orders from RoosterBio in September 2022.

About RoosterBio
RoosterBio accelerates product and process development of human mesenchymal stem/stromal cells (hMSCs) and extracellular vesicles (EVs) to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools and EV production solutions are combined with expert bioprocess knowledge to advance therapeutic developers from concept to first-in-human testing and commercial manufacturing to reduced cost and increased productivity. With optimized and scalable processes, Type 2 Drug Master Files and cGMP products, we have enabled therapeutic programs to cross their path to clinical translation in less than a year. RoosterBio is driven by the success of its customers and creating a world where safe and effective advanced therapies are rapidly developed and widely available globally.
LinkedIn: RoosterBio

About MBL Beijing
MBL Beijing Biotech Co., Ltd (called MBL Beijing for short) is a JSR Life Sciences company. The company was founded in 2005 and is 100% owned by MBL (Medical & Biological Laboratories Co., Ltd) in Japan. MBL Beijing provides both JSR and MBL products, such as magnetic microparticles, latex particles, blocking agents, protein A chromatography resins, biomarker antibodies, diagnostic raw materials, MHC tetramers, organoids, in vivo functional grade antibodies, cell culture media, etc. Based on the support of the professional technical team of their parent companies, MBL Beijing can adapt to ever-changing market demands and provide integrated enterprise programs for customers. The company is dedicated to providing high quality products and solutions to advance life science research, IVD manufacturing, pharmaceutical and biotechnology companies.
WeChat: MBLchina

Media Contact
CoqBio, Inc.
+1 301-200-5366
[email protected]
Visit us on social media:

Source link


Comments are closed.